MedTrace Logo

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

NCT00757250 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2012-02-29

No results posted yet for this study

Summary

The purpose of this study is to test the safety of an investigational medication, TXA127, and its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons infected with human immunodeficiency virus who are taking highly active anti-retroviral therapy.

Conditions

  • HIV Infections

Interventions

DRUG

Angiotensin 1-7

Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day

Sponsors & Collaborators

  • Tarix Pharmaceuticals

    collaborator INDUSTRY

  • US Biotest, Inc.

    lead INDUSTRY

Principal Investigators

  • Gere S diZerega, MD · US Biotest, Inc.

  • Robert A Larsen, MD · University of California, Keck School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757250 on ClinicalTrials.gov